'Novel drugs·CDMO competitiveness↑'
By Son, Hyung-Min | translator Kang, Shin-Kook
24.06.10 05:10:48
가나다라
0
BIO USA was held between 3-6th of June…discussions about the technology transfer of novel drugs and CDMO orders
Samsung Biologics, Lotte Biologics, and ST Pharm introduced their technological capacities…to take the place of China’s absence
Anticancer agents, ADC, and obesity pipelines have gathered attention…discussed technology transfers
Major biotech companies in Korea participated in the BIO International Convention (BIO USA 2024) and introduced their in-house competitiveness. Over 50 Korea-based companies attended the BIO USA 2024, held between June 3-6 in San Diego, United States. They sought opportunities to expand partnerships along with discussions for technology transport.
Samsung Biologics showcased its new platform, showing a strong directive to expand the company’s growth related to intensified cell-culture with improved manufacturing capacity. Lotte Biologics, ST Pharm, and Prestige Biologic introduced their contract development and manufacturing organization (CDMO) capacities and held partnering meetings for cont
Son, Hyung-Min(shm@dailypharm.com)
If you want to see the full article, please JOIN US (click)